The agreement grants worldwide rights to two clinical-stage NSCLC therapies, expanding Kairos Pharma’s oncology pipeline through a strategic asset acquisition from Celyn Therapeutics.
Kairos Pharma, Ltd. has announced the signing of a term sheet to acquire two clinical-stage oncology assets from Celyn Therapeutics, Inc., marking a significant step in its strategy to expand its footprint in targeted cancer therapeutics. The proposed transaction would grant Kairos worldwide rights to CL-273 and CL-741, two differentiated small-molecule inhibitors designed to address resistance mechanisms in non-small cell lung cancer (NSCLC), one of the largest and most challenging oncology markets globally.
Celyn Therapeutics, a privately held biotechnology company backed by leading healthcare investors including OrbiMed and Torrey Pines Investment, has advanced both programs through discovery and preclinical development. Under the contemplated agreement, Kairos would integrate these assets into its pipeline, reinforcing its focus on innovative approaches to overcoming therapeutic resistance in cancer.
Strengthening the Oncology Pipeline
Kairos Pharma, a clinical-stage biopharmaceutical company dedicated to developing therapies that reverse oncology drug resistance, views the acquisition as transformative. According to John Yu, M.D., Chief Executive Officer of Kairos Pharma, the addition of CL-273 and CL-741 would meaningfully expand the company’s development portfolio with a late-preclinical asset and a Phase 1-ready candidate in a multi-billion-dollar market characterized by substantial unmet medical needs.
The company intends to leverage its established clinical consortia on the U.S. West Coast, anchored at Cedars-Sinai Medical Center in Los Angeles, to rapidly initiate first-in-human and early-phase clinical trials. This infrastructure is expected to streamline development timelines and facilitate efficient progression into Phase 1 and Phase 2 studies should the acquisition close as planned.
Targeting EGFR and MET in NSCLC
Non-small cell lung cancer accounts for approximately 85% of all lung cancer diagnoses worldwide. A substantial subset of NSCLC cases is driven by mutations in the epidermal growth factor receptor (EGFR) gene. EGFR mutations are present in roughly 10–15% of NSCLC patients in Western populations and up to 50% in Asian populations, creating a significant global patient population eligible for targeted therapies.
While EGFR tyrosine kinase inhibitors (TKIs) have revolutionized treatment for EGFR-mutant NSCLC, resistance inevitably emerges. One of the most clinically significant mechanisms of acquired resistance is amplification or activation of the MET pathway. MET amplification enables tumor cells to bypass EGFR inhibition through compensatory signaling, limiting the durability of response to single-agent EGFR-targeted therapies.
Kairos believes that combining a pan-EGFR inhibitor with a selective c-MET inhibitor represents a scientifically validated and clinically compelling approach to overcoming both primary driver mutations and secondary resistance mechanisms. Clinical evidence from studies such as the SAVANNAH trial has demonstrated that dual inhibition of EGFR and MET pathways can meaningfully extend progression-free survival compared to single-agent strategies in EGFR-mutant, MET-amplified NSCLC patients.
CL-273: A Wild-Type-Sparing Pan-EGFR Inhibitor
CL-273 is an investigational, reversible, small-molecule pan-EGFR inhibitor specifically engineered to address the full spectrum of clinically relevant EGFR mutations in NSCLC. Developed using a proprietary artificial intelligence-driven drug discovery platform, the molecule was designed to achieve broad mutation coverage while minimizing off-target toxicity.
Preclinical studies indicate that CL-273 maintains activity against classical EGFR mutations, including exon 19 deletions and exon 21 L858R substitutions, as well as exon 20 insertions and atypical resistance-associated variants. Importantly, the compound is characterized as “wild-type-sparing,” meaning it selectively targets mutant EGFR while minimizing inhibition of the wild-type receptor found in healthy tissues.
This selectivity profile is significant because inhibition of wild-type EGFR is associated with dose-limiting toxicities such as rash and diarrhea in currently approved EGFR inhibitors. According to available preclinical data, CL-273 demonstrates a 4- to 5-fold broader therapeutic window compared to competitive agents, suggesting the potential for improved safety and tolerability.
Additionally, CL-273 has been engineered for high brain and lung permeability, an important attribute given the high incidence of central nervous system metastases in advanced NSCLC. The candidate has completed Good Laboratory Practice (GLP) toxicology studies and exhibits favorable absorption, distribution, metabolism, and excretion (ADME) properties. The program is currently in the pre-Investigational New Drug (pre-IND) stage, with first-in-human clinical trials anticipated to begin in 2026.
CL-741: A Selective Type IIb c-MET Kinase Inhibitor
Complementing CL-273 is CL-741, an orally available, small-molecule type IIb c-MET kinase inhibitor designed for high selectivity and broad coverage of activating and resistance-associated MET mutations. The compound demonstrates potent inhibition across multiple c-MET resistance mutants and is being developed for advanced solid tumors driven by MET alterations.
In NSCLC, MET exon 14 skipping mutations and MET amplification represent well-established oncogenic drivers and mechanisms of resistance to EGFR-targeted therapies. Beyond lung cancer, MET alterations are implicated in gastric, liver, and renal cancers, expanding the potential therapeutic scope of CL-741.
The c-MET inhibitor market is experiencing rapid expansion, driven by increased molecular testing and growing recognition of MET as a critical oncogenic pathway. With projections indicating significant growth through the end of the decade, CL-741 positions Kairos to participate in a high-value segment of precision oncology.
A Differentiated Dual-Target Strategy
If completed, the acquisition would enable Kairos Pharma to pursue a differentiated dual-target development strategy. By addressing both EGFR mutations and MET-mediated resistance, the company aims to deliver either best-in-class monotherapies or a rationally designed combination regimen.
Mechanistically, dual inhibition of EGFR and MET pathways has the potential to overcome compensatory signaling, deepen tumor responses, delay clonal escape, and extend progression-free survival in patients who otherwise have limited treatment options. Developing CL-273 and CL-741 in parallel provides flexibility to explore sequential or combination approaches, depending on tumor genotype and treatment history.
Combination therapy may be particularly valuable for patients who present with baseline MET amplification or who acquire MET-driven resistance following treatment with earlier-generation EGFR TKIs. Clinical precedent suggests that such combination approaches can generate meaningful response rates and survival benefits.
Expanding in a Multi-Billion-Dollar Market
The broader market context underscores the strategic importance of this acquisition. Kinase inhibitors for cancer treatment are estimated to represent a market exceeding $60 billion in 2025, with EGFR inhibitors accounting for approximately one-third of that total. The EGFR-mutant lung cancer treatment segment alone is projected to surpass $16 billion in 2026. Meanwhile, the c-MET inhibitor market, currently valued at over $2 billion, is expected to grow significantly by 2030.
By integrating CL-273 and CL-741 into its portfolio, Kairos Pharma seeks to capitalize on these growth trends while addressing persistent unmet medical needs in EGFR-mutant and MET-driven cancers.
